BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

BridgeBio Pharma (BBIO) has 4 years of Restructuring Costs data on file, last reported at $11.1 million in Q4 2025.

• For the quarter ending Q4 2025, Restructuring Costs rose 137.18% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.8 million (up 69.79% YoY), and the FY2025 full-year result was $21.3 million, up 36.8% from the prior year.
• Restructuring Costs rose to $11.1 million in Q4 2025, from $8.8 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $22.7 million in Q1 2022 to a low of $272000.0 in Q3 2023.
• A 4-year average of $5.4 million and a median of $4.1 million in 2023 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs sank 94.58% in 2023 and jumped 1598.9% in 2024, its largest moves.
• Tracing BBIO's Restructuring Costs over 4 years: stood at $7.7 million in 2022, then sank by 90.2% to $754000.0 in 2023, then soared by 522.41% to $4.7 million in 2024, then jumped by 137.18% to $11.1 million in 2025.
• Business Quant data shows BBIO's Restructuring Costs at $11.1 million in Q4 2025, $8.8 million in Q3 2025, and $805000.0 in Q2 2025.